MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

GW Pharmaceuticals plc Company Profile (LON:GWP)

Consensus Ratings for GW Pharmaceuticals plc (LON:GWP) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: GBX 176

Analysts' Ratings History for GW Pharmaceuticals plc (LON:GWP)
Show:
DateFirmActionRatingPrice TargetActions
3/15/2016Numis Securities LtdReiterated RatingUnder ReviewView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/14/2016Peel HuntReiterated RatingUnder ReviewView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for GW Pharmaceuticals plc (LON:GWP)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for GW Pharmaceuticals plc (LON:GWP)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for GW Pharmaceuticals plc (LON:GWP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for GW Pharmaceuticals plc (LON:GWP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/11/2016Guy,GeoffreyInsiderSell300,000GBX 444£1,332,000Tweet This Trade  Share This Trade on StockTwits
5/10/2016Lynch ,TomInsiderSell50,000GBX 441£220,500Tweet This Trade  Share This Trade on StockTwits
3/31/2016Wright,StephenInsiderSell58,200GBX 435£253,170Tweet This Trade  Share This Trade on StockTwits
12/18/2015Guy,GeoffreyInsiderSell6,000GBX 366£21,960Tweet This Trade  Share This Trade on StockTwits
12/10/2015Lynch ,TomInsiderSell4,270GBX 451£19,257.70Tweet This Trade  Share This Trade on StockTwits
6/12/2015James NobleInsiderSell20,000GBX 636£127,200Tweet This Trade  Share This Trade on StockTwits
6/11/2015Stephen WrightInsiderSell170,400GBX 641£1,092,264Tweet This Trade  Share This Trade on StockTwits
2/9/2015Christopher John ToveyInsiderSell10,000GBX 404.20£40,420Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for GW Pharmaceuticals plc (LON:GWP)
DateHeadline
06/27/16 04:18 PMGW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex(R) (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome
06/27/16 04:18 PMGW Pharma advances on new epilepsy drug trail success
06/06/16 07:54 AMWeeding Out the Winners in Race for Cannabis-Based Drugs - GuruFocus.com
05/20/16 03:45 AMGW Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : GWP-GB : May 20, 2016 -
05/19/16 03:41 PM3 Charts Show Why This Marijuana Stock Is Risky Business -
05/18/16 09:32 PMGW Pharmaceuticals to Present at the 2016 UBS Global Healthcare Conference on 24 May - PharmiWeb.com (press release) - GW Pharmaceuticals to Present at the 2016 UBS Global Healthcare Conference on 24 MayPharmiWeb.com (press release)LONDON, May 16, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH), (AIM:GWP), (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary ...
05/16/16 09:23 AMGW Pharmaceuticals to Present at the 2016 UBS Global Healthcare Conference on 24 May - ForexTV.com - GW Pharmaceuticals to Present at the 2016 UBS Global Healthcare Conference on 24 MayForexTV.comLONDON, May 16, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH), (AIM:GWP), (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary ...
05/13/16 04:45 PMInsider: Drug boss gives order to dealers - Interactive Investor - Insider: Drug boss gives order to dealersInteractive InvestorIt's not original, I know, but the temptation to litter an article about cannabis-based drug developer GW Pharmaceuticals (GWP) with puns is too great. But it really has been a series of highs and lows for the billion-pound firm since 2001. GW shares ...
05/13/16 04:45 PMDirector Deals - GW Pharmaceuticals PLC (GWP) - StockMarketWire.com - Dr Geoffrey Guy, Chairman, sold 300,000 shares in the company on the 11th May 2016 at a price of 444.00p. The Director now holds 13,797,852 shares. NOTE: Sold by minor family member. Average price.
05/11/16 04:55 PMDirector/PDMR Shareholding - London South East (registration) (blog) - Director/PDMR ShareholdingLondon South East (registration) (blog)Cambridge, UK, 11 May 2016: GW Pharmaceuticals (AIM: GWP, NASDAQ:GWPH) hereby provides notification that the Company has today been notified that on 10 May 2016 Thomas Lynch, a non-executive Director of the Company, sold 50,000 0.1 pence Ordinary ...and more »
05/11/16 04:55 PMGW Pharmaceuticals plc (GWP) Insider Sells £220500 in Stock - Washington News Wire - Share Trading NewsGW Pharmaceuticals plc (GWP) Insider Sells £220500 in StockWashington News WireGW Pharmaceuticals plc logo GW Pharmaceuticals plc (LON:GWP) insider Lynch ,Tom sold 50,000 shares of GW Pharmaceuticals plc stock in a transaction that occurred on Tuesday, May 10th. The stock was sold at an average price of GBX 441 ($6.35), for a ...What's GW Pharmaceuticals plc Downside After Today's Huge Decline?Franklin IndependentGw Pharmaceuticals (LON:GWP) Morning Trade VolumesShare Trading Newsall 9 news articles »
05/11/16 01:46 AMGW Pharmaceuticals Plc :GWP-GB: Earnings Analysis: Q2, 2016 By the Numbers -
05/08/16 04:49 PMLosses widen at GW Pharmaceuticals - 03/15/2016 - GW Pharmaceuticals Plc had its "outperform" rating reiterated by analysts at Cowen. GW Pharmaceuticals (GWP) has posted a loss for the six months ended 31 March 2016 of GBP34.5m (USD49.6m) compared to GBP10.9m past year. The stock now has an ...
05/06/16 09:49 PMGW Pharmaceuticals plc Reports Second Quarter and Half-Year 2016 Financial Results and Operational Progress - GlobeNewswire (press release) - Smarter AnalystGW Pharmaceuticals plc Reports Second Quarter and Half-Year 2016 Financial Results and Operational ProgressGlobeNewswire (press release)LONDON, May 05, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (AIM:GWP) (AIM:GW) (the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from ...GW Pharmaceuticals Plc (NASDAQ:GWPH) - Company Stock ReviewFranklin IndependentGW Pharmaceuticals Plc (NASDAQ:GWPH): Quick Look at Company EarningsNews TribuneGWP's losses widenStock Market Wireall 40 news articles »
05/06/16 04:42 PMFrom Stevenage to Alderley Park: the geography of British biotech - Investors Chronicle (blog) - Investors Chronicle (blog)From Stevenage to Alderley Park: the geography of British biotechInvestors Chronicle (blog)According to the BioIndustry Association, the UK has the largest pipeline of new drugs in Europe. An impressive statistic, especially considering Europe hosts some of the worlds largest pharmaceutical companies; Roche, Novartis and Sanofi to name a few.
05/06/16 04:42 PMGW Pharma's Disappointing News from its Conference Call that Nobody Noticed - New Cannabis Ventures (blog) - New Cannabis Ventures (blog)GW Pharma's Disappointing News from its Conference Call that Nobody NoticedNew Cannabis Ventures (blog)Such was the case with GW Pharma (NASDAQ:GWPH) (LON:GWP), which reported its Q2 today. Today's press release neglected to mention the timing of the New Drug Application (NDA) filing with the FDA for its epilepsy drug, Epidiolex. The timing is crucial ...
05/05/16 05:05 PMGW Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference on 10 May - GlobeNewswire (press release) - GW Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Healthcare Conference on 10 MayGlobeNewswire (press release)LONDON, May 04, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary ...and more »
05/05/16 05:05 PMGW Pharma Initial Phase 3 Clinical Trial Results for Epidiolex to Treat Lennox-Gastaut Syndrome Ahead as Company ... - New Cannabis Ventures (blog) - NasdaqGW Pharma Initial Phase 3 Clinical Trial Results for Epidiolex to Treat Lennox-Gastaut Syndrome Ahead as Company ...New Cannabis Ventures (blog)LONDON, May 05, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (AIM:GWP) (AIM:GW) (the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from ...GW Pharmaceuticals Plc (NASDAQ:GWPH): Quick Look at Company EarningsNews TribuneGWP's losses widenStock Market Wireall 32 news articles »
05/05/16 10:40 AMEdited Transcript of GWP.L earnings conference call or presentation 5-May-16 1:00pm GMT -
05/05/16 06:07 AMHalf Year 2016 GW Pharmaceuticals PLC Earnings Release - Time Not Supplied -
04/28/16 05:04 PMGW Pharmaceuticals to Report Q2, Half-Year Financial Results and Host Conference Call on 5 May, 2016 - PharmiWeb.com (press release) - GW Pharmaceuticals to Report Q2, Half-Year Financial Results and Host Conference Call on 5 May, 2016PharmiWeb.com (press release)LONDON, April 28, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary ...and more »
04/25/16 05:39 PMNew Report Available: GW Pharmaceuticals Plc (GWP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile - (live-PR.com) - GW Pharmaceuticals plc (GW Pharmaceuticals) is a biopharmaceutical company which discovers, develops and commercializes innovative therapeutics from its proprietary cannabinoid product platform. The company's product Sativex is a plant ...
04/24/16 10:28 PMSuccess stories leave medical cannabis companies on a high - The Pharma Letter (registration) - The Pharma Letter (registration)Success stories leave medical cannabis companies on a highThe Pharma Letter (registration)And it would now appear that, slowly but surely, its medicinal reputation is being restored thanks to pioneering companies like the UK's GW Pharmaceutical (LSE: GWP), INSYS Therapeutics (Nasdaq: INSY) and Israel's One World Cannabis who are throwing ...
04/21/16 10:15 PMGW Pharmaceuticals Plc (NASDAQ:GWPH): Where are Shares Headed? - News Tribune - GW Pharmaceuticals Plc (NASDAQ:GWPH): Where are Shares Headed?News TribuneResearch analysts covering GW Pharmaceuticals Plc (NASDAQ:GWPH) shares have provided price target projections on the popular stock. They project that the shares are expected to reach $146.6 within the upcoming year. This consensus number they've ...and more »
04/21/16 10:15 PMGW Pharmaceuticals Receives Orphan Drug Designation from FDA for Cannabidiol for the Treatment of Tuberous ... - GlobeNewswire (press release) - Proactive Investors UKGW Pharmaceuticals Receives Orphan Drug Designation from FDA for Cannabidiol for the Treatment of Tuberous ...GlobeNewswire (press release)LONDON, April 21, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary ...Orphan Drug Designation for GW's cannabis seizure treatmentProactive Investors UKall 7 news articles »
04/21/16 05:05 PMGW Pharma's Epidiolex Gains 3rd FDA Orphan Drug Designation - New Cannabis Ventures (blog) - Proactive Investors UKGW Pharma's Epidiolex Gains 3rd FDA Orphan Drug DesignationNew Cannabis Ventures (blog)LONDON, April 21, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary ...Orphan Drug Designation for GW's cannabis seizure treatmentProactive Investors UKall 6 news articles »
04/21/16 05:05 PMOrphan Drug Designation for GW's cannabis seizure treatment - Biotech group GW Pharmaceuticals PLC (NASDAQ:GWPH LON:GWP) has been granted exclusive approval for its cannabis-based seizure treatment. The US Food and Drug Administration (FDA) has granted Orphan Drug Designation for the group’s cannabidiol (CBD ...
04/15/16 10:48 AMThese 3 Marijuana-Related Stocks Are Poised for Strong Growth -
04/12/16 05:00 PMGW Pharmaceuticals Initiates Phase 3 Pivotal Study In Tuberous Sclerosis Complex - Clinical Leader - GW Pharmaceuticals Initiates Phase 3 Pivotal Study In Tuberous Sclerosis ComplexClinical LeaderLondon, (GLOBE NEWSWIRE) - GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid ...and more »
04/12/16 09:40 AMGW Pharmaceuticals Begins Another Phase III Epidiolex Trial -
04/11/16 04:52 PMGW Pharmaceuticals plc ( GWP ) - London, UK, 11 Apr 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today ...
04/11/16 08:22 AMGW Pharmaceuticals Launches Epidiolex Phase 3 Trial for 3rd Indication, TSC - New Cannabis Ventures (blog) - GW Pharmaceuticals Launches Epidiolex Phase 3 Trial for 3rd Indication, TSCNew Cannabis Ventures (blog)LONDON, April 11, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary ...and more »
04/11/16 07:20 AM11/04/2016 GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex - [at noodls] - 8c274c5f-bc69-44c3-b031-2683f9372e6c.pdf April 11, 2016 GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex LONDON, April 11, 2016 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc ...
04/11/16 06:00 AMGW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex - [GlobeNewswire] - LONDON, April 11, 2016-- GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, ...
04/05/16 02:03 PMWhy This Marijuana Stock Sky-Rocketed 79% in March -
04/04/16 08:35 AMGW Pharmaceuticals plc (GWP) Insider Sells £253170 in Stock - MicroCap Magazine - GW Pharmaceuticals plc (GWP) Insider Sells £253170 in StockMicroCap MagazineGW Pharmaceuticals plc logo GW Pharmaceuticals plc (LON:GWP) insider Wright,Stephen sold 58,200 shares of GW Pharmaceuticals plc stock in a transaction on Thursday, March 31st. The stock was sold at an average price of GBX 435 ($6.19), for a total ...and more »
03/30/16 04:53 PMGw Pharmaceuticals (LON:GWP) Morning Trade Activity - Share Trading News - Share Trading NewsGw Pharmaceuticals (LON:GWP) Morning Trade ActivityShare Trading NewsAt 12:18pm on Wednesday 30th of March roughly 41,578 shares in Gw Pharmaceuticals (LON:GWP) during the morning had been sold by investors whilst 44,027 were purchased making 51.43 percent of the shares being traded on the buy side of the market.
03/30/16 07:22 AMWhat Next for GW Pharmaceuticals plc Stock After Today's Huge Decline? - Stock Caller - What Next for GW Pharmaceuticals plc Stock After Today's Huge Decline?Stock CallerThe stock of GW Pharmaceuticals plc (LON:GWP) is a huge mover today! The stock decreased 6.67% or GBX 31.44 on March 29, hitting GBX 440.06. About 567,294 shares traded hands. GW Pharmaceuticals plc (LON:GWP) has declined 20.66% since ...and more »
03/29/16 08:44 AMShare Activity Review: GW Pharmaceuticals plc( NASDAQ:GWPH ) - Guernsey Pharmaceuticals Limited and GWP Trustee Company Limited. According to Zacks Investment Research, "GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary ...
03/29/16 08:35 AM8 Major Biopharma Events Coming Later in 2016 and in 2017 -
03/29/16 08:24 AMU.S. firms target investment in Israeli cannabis R&D -
03/27/16 01:02 PMThese Two Stocks Are On Different Paths, But Both Remain Risky -
03/23/16 09:42 PMGw Pharmaceuticals (LON:GWP) Largest Morning Trades - Share Trading News - Share Trading NewsGw Pharmaceuticals (LON:GWP) Largest Morning TradesShare Trading NewsAt 12:17pm on Wednesday 23rd of March roughly 82,094 shares in Gw Pharmaceuticals (LON:GWP) during the morning had been sold by investors whilst 112,436 were purchased making 57.80 percent of the shares being traded on the buy side of the ...
03/21/16 04:59 PMMorning Shares Trades Of Gw Pharmaceuticals (LON:GWP) - Share Trading News - Share Trading NewsMorning Shares Trades Of Gw Pharmaceuticals (LON:GWP)Share Trading NewsAt 12:18pm on Monday 21st of March roughly 42,618 shares in Gw Pharmaceuticals (LON:GWP) during the morning had been sold by investors whilst 45,505 were purchased making 51.64 percent of the shares being traded on the buy side of the market.
03/21/16 09:32 AMWhich Biotech Stocks and ETFs Topped the Sector Last Week? -
03/21/16 08:50 AMWhy GW Pharma Could More Than Double From Cannabinoid Drugs -
03/21/16 07:27 AMUp 300%+ In 5 Years: CVS Group Plc, GW Pharmaceuticals Plc And Pantheon Resources Plc - The Motley Fool UK - Up 300%+ In 5 Years: CVS Group Plc, GW Pharmaceuticals Plc And Pantheon Resources PlcThe Motley Fool UKDo five-year increases in share prices of 685% at CVS Group (LSE: CVSG), 437% at GW Pharmaceuticals (LSE: GWP), and 314% at Pantheon Resources (LSE: PANR), make these three a handful of the best shares most investors have never heard of?and more »
03/21/16 05:40 AMUp 300%+ In 5 Years: CVS Group Plc, GW Pharmaceuticals Plc And Pantheon Resources Plc -
03/15/16 03:39 PMFive things to know about what could be America’s first cannabis-derived drug -
03/15/16 11:21 AMA Huge Breakthrough For Medical Marijuana -
About GW Pharmaceuticals plc

GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies. The Company operates through three segments: Commercial, Sativex Research and Development (Sativex R&D), and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex R&D segment seeks to maximize the potential of Sativex through the development of indications. The Sativex R&D segment focuses on the Phase III clinical development program of Sativex for use in the treatment of cancer pain. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using the Company's cannabinoid technology platform.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: GWP
  • CUSIP:
Key Metrics:
  • Previous Close: $7.47
  • 50 Day Moving Average: $498.65
  • 200 Day Moving Average: $399.75
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.49B
  • Current Quarter EPS Consensus Estimate: $-25.35 EPS
Additional Links:

            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha